Attralus Presents New Preclinical Data on AT-04 and AT-07, Pan-Amyloid Removal Therapeutics Targeting Neurodegenerative Disorders, at AD/PD 2023
03 avr. 2023 07h00 HE
|
Attralus, Inc
AT-04 demonstrated sub nanomolar binding to Aβ, tau and α-synuclein fibrilsAT-04 demonstrated in vivo target engagement and binding to Aβ plaques in the brainAT-07 (AT-04 + Brain Shuttle) demonstrated...
Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders
17 nov. 2022 07h00 HE
|
Attralus, Inc
SAN FRANCISCO and PHILADELPHIA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with...
Alzheimer’s Patient Advocates File FOIA Seeking Answers on Discriminatory Medicare Coverage Decision
15 avr. 2022 11h42 HE
|
UsAgainstAlzheimer's
Washington, D.C., April 15, 2022 (GLOBE NEWSWIRE) -- Today, UsAgainstAlzheimer’s announced their latest effort to demand answers from the Centers for Medicare and Medicare Services (CMS) about last...
NIH Awards Cerebral Amyloid Angiopathy Grant to Amydis Diagnostics
09 oct. 2017 09h14 HE
|
Amydis Diagnostics, Inc.
SAN DIEGO, Oct. 09, 2017 (GLOBE NEWSWIRE) -- Amydis Diagnostics, Inc., a privately-held pharmaceutical company developing proprietary chemistry and innovative approaches for the detection of...
Amydis Diagnostics Named to San Diego Venture Group’s (SDVG) 2017 Cool Companies List
30 mai 2017 09h00 HE
|
Amydis Diagnostics, Inc.
SAN DIEGO, May 30, 2017 (GLOBE NEWSWIRE) -- Amydis Diagnostics, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to...
Amydis Diagnostics Adds Veteran Drug Development Executive and Chief Medical Officer to Management Team
17 mai 2017 09h00 HE
|
Amydis Diagnostics, Inc.
SAN DIEGO, May 17, 2017 (GLOBE NEWSWIRE) -- Amydis Diagnostics, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to...
Amydis Diagnostics Awarded NIH Grant to Further Investigate Innovative Technology for Early Detection of Alzheimer’s Disease
20 mars 2017 07h07 HE
|
Amydis Diagnostics, Inc.
SAN DIEGO, March 20, 2017 (GLOBE NEWSWIRE) -- Amydis Diagnostics, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to...
Elsevier Announces Timely New Book, "Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer's Disease"
01 nov. 2016 04h00 HE
|
Elsevier, Inc.
CAMBRIDGE, MA--(Marketwired - November 01, 2016) - Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of Drug...
Elsevier Publishes New Book on Developing Therapeutics for Alzheimer's Disease
21 juil. 2016 04h00 HE
|
Elsevier, Inc.
CAMBRIDGE, MA--(Marketwired - July 21, 2016) - Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of Developing...
Amydis Diagnostics Awarded NIA-NIH Grant to Investigate Innovative Technology for Detection of Alzheimer's Disease
29 sept. 2015 09h00 HE
|
Amydis, Inc.
SAN DIEGO, Sept. 29, 2015 (GLOBE NEWSWIRE) -- Amydis Diagnostics, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to...